Horizon hit by Actimimmune fail in Friedrich’s ataxia
Horizon Pharma shares dropped 20 percent after the company pulled the plug a late-stage trial testing Actimmune as a potential therapy Friedreich’s ataxia.
Read More
Tag: Actimmune
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
